Management Communication — C204 Task One.docx Task A: To: All Staff From: Mel Co Management Team RE: Nasaquil All, Because of your dedication, relationships and hard work, our company has been awarded the exclusive
...
Management Communication — C204 Task One.docx Task A: To: All Staff From: Mel Co Management Team RE: Nasaquil All, Because of your dedication, relationships and hard work, our company has been awarded the exclusive contract to distribute a new medication that treats influenza called Nasaquil. A few advantages of this new medication are: A: Nasaquil will help lower the severity of influenza symptoms and the duration of influenza. B: Nasaquil is over the counter – No more waiting in line at the pharmacy or looking for after-hours pharmacys to pick up the prescription. Some medical professionals or consumers might bring up a concerns or disadvantages such as: A: This drug is so new it has only had limited clinical trials, and because of this long term efficacy has not been determined. To this we would say, despite the medication not having long term trials, it has been cleared for sale by the FDA to be sold over the counter, which is not done without proper testing. In addition, if there are customers who are not satisfied with the results of the drug, they will be handled on a case-by-case basis with the consumer. B: Availability- When purchased, the product has to be shipped overnight in a refrigerated container. This can be seen as a positive and a negative in that you will not be able to just pick up the drug and start taking it immediately. We want this to be spun as a positive so that the consumer and medical professional know that the medication is the freshest and safest it can be coming over night s. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .. . . . . .. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .. . .. .. . . . . . . . . . . . . . . . . . .. . . . .
[Show More]